Histology, mutation, and response to chemotherapy in TNBC PDX derived from residual tumors after neoadjuvant chemotherapy
| PDX response: % TGI and RECIST criteria | |||||||
|---|---|---|---|---|---|---|---|
| PDX | Neoadjuvant treatment of TNBC patients | Tumor histology | TP53 and BRCA1/2 mutations | AC | Docetaxel | Cisplatin | Capecitabine |
| HBCx-12A | Docetaxel | IDC | None | 44 (PD) | 28 (PD) | 0 (PD) | 96 (SD) |
| HBCx-39 | EC + docetaxel | IDC | TP53 | 36 (PD) | 0 (PD | 16 (PD) | 98 (R) |
| HBCx-48 | FEC docetaxel | IDC | TP53 | 30 (PD) | 0 (PD) | 40 (PD) | 37 (PD) |
| HBCx-63 | FEC docetaxel | IDC | TP53 | 74 (PD) | 30 (PD) | 86 (PD) | 96 (SD) |
| HBCx-66 | FEC docetaxel | MBC | BRCA1 | 94 (R) | 0 (PD) | 98 (R) | 41.4 (PD) |
| HBCx-69 | FEC docetaxel | MBC | TP53 | 31 (PD) | 50 (PD) | 64 (PD) | 55 (PD) |
| HBCx-92 | EC docetaxel | IDC | BRCA2 | 74 (PD) | 30 (PD) | 90 (PD) | 93 (SD) |
| HBCx-90 | Paclitaxel | MBC | TP53 | 81 (PD) | 35 (PD) | 89 (PD) | 0 (PD) |
| HBCx-95 | FEC docetaxel | IDC | None | 0 (PD) | 32 (PD) | 50 (PD) | 100 (R) |
| HBCx-106 | FEC docetaxel | IDC | TP53 | 75 (PD) | 43 (PD) | 69 (PD) | 90 (SD) |
Abbreviations: AC, adriamycin + cyclophosphamide; CR, complete response; FEC, 5-FU, epirubicin, cyclophosphamide; IDC, invasive ductal carcinoma; MBC, metaplastic breast cancer; PD, progressive disease; R, regression; SD, stable disease; TGI, tumor growth inhibition.